Latest News

• share
• favorite_border

NCCN 2023 Annual Conference featuring more than a thousand worldwide oncology professionals will present new research findings, latest NCCN Guidelines updates, and best practices for achieving quality cancer care delivery, in Orlando and online March 31—April 2, 2023. Visit NCCN.org/conference for more.

• share
• favorite_border

The National Comprehensive Cancer Network® (NCCN®)—a not-for-profit alliance of leading United States cancer centers—announces a new collaboration with the Institute of Hematology and Transfusion Medicine in Poland (IHIT), and the Alliance For Innovation—Polish-American Foundation (AFI).

• share
• favorite_border

New research in the February 2023 issue of JNCCN—Journal of the National Comprehensive Cancer Network illustrates how the use of an algorithm to calculate a patient-reported symptom complexity score can help oncologists identify patients who are at increased risk for unplanned visits to the emergency department (ED), creating the potential for additional proactive care, and the reduction of healthcare costs.

• share
• favorite_border

An ongoing pilot project aims to evaluate the feasibility of implementing the Health Equity Report Card (HERC) as a tool for improving the quality and equity of cancer care and continues the Elevating Cancer Equity collaboration from the National Comprehensive Cancer Network (NCCN), American Cancer Society Cancer Action Network (ACS CAN), and National Minority Quality Forum (NMQF)--highlighted on World Cancer Day.

• share
• favorite_border

National Comprehensive Cancer Network’s new Diversity, Equity, & Inclusion (DEI) Directors Forum is working together to improve diversity of clinical staff representation across nation’s leading academic cancer centers.

• share
• favorite_border

New research in JNCCN finds that immunotherapy from immune checkpoint (PD-1) inhibitors prior to surgery was strikingly effective for patients with localized mismatch repair-deficient or microsatellite instability-high (dMMR/MSI-H) colorectal cancer (CRC).

• share
• favorite_border

NCCN is working on new NCCN Harmonized Guidelines™ for Sub-Saharan Africa, in collaboration with the African Cancer Coalition (ACC), the American Cancer Society (ACS), and the Clinton Health Access Initiative (CHAI). The organizations are part of Allied Against Cancer, a global multi-sector effort to improve resource-stratified access to life-saving cancer care in Sub-Saharan Africa.

• share
• favorite_border

New research in JNCCN finds that only 30% of patients with advanced neuroendocrine tumors (NETs) say their top goal for treatment is living longer. Only 51.7% of patients perceived that they had the same treatment goals as their physician.

• share
• favorite_border

Annual NCCN Patient Advocacy Summit explores stories and data highlighting barriers to high-quality care that LGBTQ+ people with cancer experience, examining persistent setbacks and promising developments.

• share
• favorite_border

National Comprehensive Cancer Network and the Latin American and Caribbean Society of Medical Oncology collaborate to address policy and practice solutions to increase equitable access for breast cancer care, starting in Argentina and then expanding more broadly.

• share
• favorite_border

The National Comprehensive Cancer Network’s Oncology Research Program selects projects focused on improving patient care and outcomes in locally advanced or metastatic bladder cancer.

• share
• favorite_border

A study in JNCCN, led by researchers at Duke University School of Medicine, found that Non-Hispanic Black patients were less likely to receive guideline-appropriate treatment for ovarian cancer compared to Non-Hispanic White patients, even after adjusting for healthcare access issues.

• share
• favorite_border

United States-based National Comprehensive Cancer Network enters strategic cooperation agreement with Chinese medical information website to publish and translate evidence-based expert consensus guidelines for cancer care; now available at nccnchina.org.cn.

• share
• favorite_border

The National Comprehensive Cancer Network® (NCCN®)—an alliance of leading cancer centers devoted to patient care, research, and education—has been named winner for the 2022 Excellence in Cancer Patient Education award from the Cancer Patient Education Network (CPEN).

• share
• favorite_border

New research published in the October 2022 issue of JNCCN—Journal of the National Comprehensive Cancer Network confirms the safety of mRNA vaccines in people with cancer undergoing immunotherapy treatment.

• share
• favorite_border

On World Mental Health Day, NCCN announced an updated NCCN Distress Thermometer, is available in more than 70 languages, to help people around the world identify and address psychosocial stressors that may raise challenges when coping with having cancer, its symptoms, or treatment.

• share
• favorite_border

The 2022 NCCN Annual Congress on Hematologic Malignancies™ (#NCCNhem22) is taking place Friday, October 14–Saturday, October 15, 2022 in New York City. All live sessions will also stream remotely through a virtual event platform.

• share
• favorite_border

National Comprehensive Cancer Network Advisory Committee on COVID-19 Vaccination and Pre-exposure Prophylaxis details clarified expert consensus to help guide providers on latest data and information, available at NCCN.org/covid-19.

• share
• favorite_border

National Comprehensive Cancer Network’s #NCCNPolicy Summit, featuring White House Moonshot Coordinator and representatives from CDC, NCI, and USPSTF, examines critical need for improvements in cancer prevention and early detection across the United States.

• share
• favorite_border

The new patient guidelines for Marginal Zone Lymphoma guidelines are the latest in NCCN’s library of NCCN Guidelines for Patients®, published through funding from the NCCN Foundation® and available online free of charge.

• share
• favorite_border

New research in the September 2022 issue of JNCCN—Journal of the National Comprehensive Cancer Network finds the use of positron emission tomography (PET) with 18-fluorodeoxyglucose (FDG) tracer adds significant prognostic benefit in objectively assessing neoadjuvant chemotherapy response in borderline resectable/locally advanced pancreatic cancer patients prior to surgery.

• share
• favorite_border

The National Comprehensive Cancer Network’s Oncology Research Program is collaborating with Pfizer and Myovant to address cardiovascular risk in patients with prostate cancer being treated with androgen deprivation therapy (ADT).

• share
• favorite_border

Gerontology researchers teamed up with hematologic-oncology investigators from Brigham and Women’s Hospital and the Dana-Farber Cancer Institute to look at the association between older patients with blood cancers who were taking multiple medications and their corresponding frailty. They also created a new scale based on a list of Potentially Inappropriate Medications (PIMs) from the NCCN Guidelines® for Older Adult Oncology—called the Geriatric Oncology-Potentially Inappropriate Medications (GO-PIMs) Scale—and found it to be more effective at predicting frailty than conventional methods.

• share
• favorite_border

Patients seeking to purchase chemotherapy drugs online face a confusing array of websites, over half of which potentially operate unsafely or illegally, finds a new study in the July 2022 issue of JNCCN—Journal of the National Comprehensive Cancer Network. A survey of online pharmacies claiming to sell the oral chemotherapy drug imatinib found that only three of the 44 identified English-language sites that shipped within the United States were certified through the LegitScript online pharmacy monitoring service.

• share
• favorite_border

The National Comprehensive Cancer Network (NCCN) has published new NCCN Guidelines for Patients: Breast Cancer Screening and Diagnosis to help people understand their personal risk for breast cancer, when they should begin screening, and how often to screen—in order to detect cancer earlier, for more treatment options and better outcomes.

• share
• favorite_border

Newly-published NCCN Guidelines for Pediatric Central Nervous System Cancers synthesize latest evidence to help care teams ensure children with high-grade gliomas have best possible outcomes; available free at NCCN.org.

• share
• favorite_border

New population study in JNCCN on adjuvant hormone therapy for breast cancer finds correlation between hot flashes and poorer outcomes—in contrast to clinical trial results; likely due to patients with side-effects ending treatment early.

• share
• favorite_border

The National Comprehensive Cancer Network (NCCN) convened an oncology policy summit in Washington D.C. on building a workplace that includes support for people with cancer and their caregivers. The program, which also featured a virtual attendance option, examined how workplace norms and expectations have changed in recent years, particularly since the onset of the COVID-19 pandemic.

• share
• favorite_border

National Comprehensive Cancer Network honors oncology leaders: Robert Winn, MD, and Shonta Chambers, MSW, named joint Partners in Cancer Care; William Gradishar, MD, named Rodger Winn Award recipient for work on NCCN Guidelines; Hema Sundar, PhD, named Employee of the Year.

• share
• favorite_border

A new study in JNCCN finds patients with cancer who smoke are more likely to receive evidence-based cessation assistance by using the ELEVATE program, increasing the likelihood of better outcomes.

• share
• favorite_border

National Comprehensive Cancer Network Advisory Committee on COVID-19 Vaccination and Pre-exposure Prophylaxis provides expert consensus to help guide cancer care providers on latest research, available at NCCN.org/covid-19.

• share
• favorite_border

National Comprehensive Cancer Network’s Oncology Research Program to oversee projects from early-career investigators advancing key areas for study in cancer care and biology, such as novel combination therapy, equitable access to cellular therapies, immune cell dysfunction, liquid biomarkers, genetic ancestry, oncogenic vulnerabilities, and MAIT cell antitumor activity.

• share
• favorite_border

The National Comprehensive Cancer Network—a non-profit based in the United States—is providing free patient-tailored cancer treatment guides to help Ukrainians with cancer get the best possible care, available online at NCCN.org/Ukraine.

• share
• favorite_border

Research in the April 2022 issue of JNCCN finds rates of breast cancer survivors receiving annual mammograms dropped 1.5% per year from 2009 to 2016, with largest decrease in survivors under age 50.

• share
• favorite_border

The National Comprehensive Cancer Network® (NCCN®) announces the election of John W. Sweetenham, MD, FRCP, FACP, FASCO, to the role of Chair of the Board of Directors and Matt Kalaycio, MD, FACP, as Vice-Chair.

• share
• favorite_border

National Comprehensive Cancer Network® (NCCN®) announces Indiana University Melvin and Bren Simon Comprehensive Cancer Center will be joining the not-for-profit alliance of leading cancer centers as the 32nd Member Institution.

• share
• favorite_border

Three-day #NCCN2022 virtual oncology conference from National Comprehensive Cancer Network includes more than 30 educational sessions on the latest in cancer care plus more than 200 electronic posters presenting new research in oncology.

• share
• favorite_border

NCCN Guidelines for Patients: Colorectal Cancer Screening now translated into multiple languages to help people worldwide understand why, when and how to screen for colorectal cancer.

• share
• favorite_border

Research in the March 2022 issue of JNCCN examined the impact of the COVID-19 pandemic on the number of new cancer cases detected. They found the week-to-week rate of diagnosis was steady before the pandemic, but dropped 34.3% in March of 2020.

• share
• favorite_border

The National Comprehensive Cancer Network publishes two new NCCN Guidelines for Malignant Peritoneal Mesothelioma and for Ampullary Adenocarcinoma, to standardize treatment and improve outcomes for these rare tumor types; also reaches milestone expanding library of NCCN Chemotherapy Order Templates.

• share
• favorite_border

Senators Ben Cardin (D-MD) and Lisa Murkowski (R-AK) introduced the Reducing Hereditary Cancer Act, bipartisan legislation to expand access to medically-appropriate genetic testing to determine an individual’s risk of developing hereditary cancer—and access to evidence-based medical care to reduce risk for those who have a predisposing genetic mutation.

• share
• favorite_border

Researchers at Fox Chase Cancer Center conducted the largest published, peer-reviewed, study to-date examining the short-term adverse effects of mRNA COVID-19 vaccination in patients with cancer—finding they experienced no more, and no different, side effects compared to non-cancer patients.

• share
• favorite_border

Global nonprofit National Comprehensive Cancer Network participates in annual World Cancer Day, every February 4. This year's campaign highlights cancer care disparities and free resources to help, detailed at NCCN.org/wcd.

• share
• favorite_border

The National Comprehensive Cancer Network’s Oncology Research Program to oversee projects focused on improving patient care and outcomes in lung and thyroid cancers.

• share
• favorite_border

New research in the January 2022 issue of JNCCN—Journal of the National Comprehensive Cancer Network examined the impact of septic shock on people with hematologic malignancies, finding 67.8% died in fewer than 28 days and only 19.4% remained alive after 90 days.

• share
• favorite_border

New NCCN Guidelines for Patients: Graft-Versus-Host Disease offers clarity and consensus on how best to address and treat a common and complex immune response side-effect from stem cell transplants.

• share
• favorite_border

The National Comprehensive Cancer Network (NCCN) publishes updated guidance on vaccination and pre-exposure prophylaxis of COVID-19 for people with cancer based on latest FDA approvals and surging COVID-19 infection rates—available at NCCN.org/covid-19.

• share
• favorite_border

The National Comprehensive Cancer Network’s Oncology Research Program to oversee projects focused on the use of talazoparib in treating people with prostate cancer.

• share
• favorite_border

In a new study in the December 2021 issue of JNCCN—Journal of the National Comprehensive Cancer Network researchers examined published randomized control trials supporting FDA approval for treatments for solid tumors from January 2015 through December 2019—and found that for 33 out of 81 studies, it was not clear in the publication why or how patients were being censored (i.e. removed from follow-up before experiencing the outcome of interest).

• share
• favorite_border

NCCN has published new NCCN Guidelines for Patients®: Cervical Cancer to help people with cervical cancer become more informed, suggest what conversations to have with their doctor, and be active decision makers in their treatment. They are available online free of charge at NCCN.org/patientguidelines.